[go: up one dir, main page]

NO990428L - Difenylheterocykler som kalsium-kanal-modulatorer - Google Patents

Difenylheterocykler som kalsium-kanal-modulatorer

Info

Publication number
NO990428L
NO990428L NO990428A NO990428A NO990428L NO 990428 L NO990428 L NO 990428L NO 990428 A NO990428 A NO 990428A NO 990428 A NO990428 A NO 990428A NO 990428 L NO990428 L NO 990428L
Authority
NO
Norway
Prior art keywords
calcium channel
channel modulators
diphenyl heterocycles
heterocycles
diphenyl
Prior art date
Application number
NO990428A
Other languages
English (en)
Other versions
NO990428D0 (no
Inventor
Jeffrey L Romine
Scott W Martin
Piyasena Hewawasam
Nicholas A Meanwell
Valentin K Gribkoff
Jr John E Starrett
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO990428L publication Critical patent/NO990428L/no
Publication of NO990428D0 publication Critical patent/NO990428D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO990428A 1996-07-31 1999-01-29 Difenylheterocykler som kalsium-kanal-modulatorer NO990428D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2298396P 1996-07-31 1996-07-31
PCT/US1997/014352 WO1998004135A1 (en) 1996-07-31 1997-07-30 Diphenyl heterocycles as potassium channel modulators

Publications (2)

Publication Number Publication Date
NO990428L true NO990428L (no) 1999-01-29
NO990428D0 NO990428D0 (no) 1999-01-29

Family

ID=21812455

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990428A NO990428D0 (no) 1996-07-31 1999-01-29 Difenylheterocykler som kalsium-kanal-modulatorer

Country Status (18)

Country Link
US (3) US5869509A (no)
EP (1) EP0915856A4 (no)
JP (1) JP2000516925A (no)
KR (1) KR20000029735A (no)
CN (1) CN1116287C (no)
AR (1) AR008110A1 (no)
AU (1) AU711736B2 (no)
BR (1) BR9710793A (no)
CZ (1) CZ32199A3 (no)
HU (1) HUP0000063A3 (no)
IL (1) IL128308A (no)
NO (1) NO990428D0 (no)
NZ (1) NZ334403A (no)
PL (1) PL331385A1 (no)
RU (1) RU2175319C2 (no)
TW (1) TW467902B (no)
WO (1) WO1998004135A1 (no)
ZA (1) ZA976554B (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
AU736599B2 (en) * 1998-01-29 2001-08-02 Bristol-Myers Squibb Company Amino acid derivatives of diaryl 1,3,4-oxadiazolone
AU736712B2 (en) * 1998-01-29 2001-08-02 Bristol-Myers Squibb Company Benzoate derivatives of diaryl 1,3,4-oxadiazolone
HUP0102025A3 (en) * 1998-01-29 2002-01-28 Bristol Myers Squibb Co Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use
CA2318817A1 (en) * 1998-01-29 1999-08-05 Bristol-Myers Squibb Company Phosphate derivatives of diaryl 1,3,4-oxadiazolone
DE19816882A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
AU771471B2 (en) * 1999-01-29 2004-03-25 Bristol-Myers Squibb Company Carbamate derivatives of diaryl 1,3,4-oxadiazolone
US6297241B1 (en) 1999-01-29 2001-10-02 Bristol-Myers Squibb Company Carbamate derivatives of diaryl 1,3,4-oxadiazolone
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US20050153940A1 (en) * 2000-01-26 2005-07-14 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
AU2002213204A1 (en) * 2000-10-13 2002-04-22 Bristol-Myers Squibb Company Selective maxi-K- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
DE10056344A1 (de) * 2000-11-14 2002-05-16 Degussa n-Propylethoxysiloxane, Verfahren zu deren Herstellung und deren Verwendung
DE10058461A1 (de) * 2000-11-24 2002-09-19 Bayer Ag Substituierte Cyclohexanderivate und ihre Verwendung
US6855829B2 (en) 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
MXJL03000027A (es) * 2001-03-12 2004-04-30 Avanir Pharmaceuticals Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
EP1432690A2 (en) * 2001-04-16 2004-06-30 Tanabe Seiyaku Co., Ltd. Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
US7022480B1 (en) 2001-10-11 2006-04-04 The Regents Of The University Of California Exons of the hSKCa3/KCNN3 gene
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
US6613786B2 (en) 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
US7846671B2 (en) * 2002-01-28 2010-12-07 Bristol-Myers Squibb Company Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
TWI271402B (en) 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
KR20050120711A (ko) * 2003-04-10 2005-12-22 아바니르 파마슈티컬스 알레르기 및 세포 과다증식 질병의 치료를 위한 이미다졸유도체
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
JP2007501618A (ja) * 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法
CA2560954A1 (en) * 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
WO2005100340A2 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
CA2574308C (en) 2004-07-27 2014-03-25 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
US7902235B2 (en) 2004-10-13 2011-03-08 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
PL1817295T3 (pl) 2004-11-18 2013-04-30 Synta Pharmaceuticals Corp Związki triazolowe, które modulują aktywność HSP90
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
JP5683787B2 (ja) 2005-08-18 2015-03-11 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するイミダゾール化合物
AU2006338265B2 (en) 2005-08-18 2011-04-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
AU2007267860B2 (en) * 2006-05-25 2012-08-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
AU2007267852A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate Hsp90 activity and methods for identifying same
TW200804313A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
PT2035396E (pt) 2006-05-25 2014-07-29 Synta Pharmaceuticals Corp Compostos de triazol que modulam a atividade da hsp90
US20100137327A1 (en) * 2007-01-18 2010-06-03 Neurosearch A/S Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
CN101657433A (zh) 2007-03-29 2010-02-24 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
EP2152677A1 (en) * 2007-05-03 2010-02-17 NeuroSearch A/S Acetamide derivatives as potassium channel modulators
WO2009125870A1 (en) 2008-04-09 2009-10-15 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
PE20091953A1 (es) * 2008-05-08 2010-01-09 Du Pont Azoles sustituidos como fungicidas
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
SG11201504622PA (en) 2012-12-20 2015-07-30 Inception 2 Inc Triazolone compounds and uses thereof
CA2921420A1 (en) 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
BR112017003918B1 (pt) 2014-08-29 2022-05-03 Fmc Corporation Composto, composições e mistura herbicida e método para o controle do crescimento da vegetação
CN104710379B (zh) * 2015-03-09 2017-01-18 华南理工大学 一种bms‑191011的合成方法
WO2020086149A1 (en) * 2018-10-26 2020-04-30 University Of South Florida Drug for treating tinnitus
CN115504940A (zh) * 2021-06-23 2022-12-23 中国科学院上海药物研究所 一种酰胺类化合物、其制备方法和制药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545646B1 (de) * 1965-12-15 1969-09-18 Boehringer Sohn Ingelheim 1,3-Dimethyl-4-(2',4'-dichlorphenyl)-1,2,4-triazolon-(5) und Verfahren zu dessen Herstellung
CH583213A5 (no) * 1973-05-21 1976-12-31 Ciba Geigy Ag
DE2940709A1 (de) * 1979-10-08 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von in 1-stellung substituierten imidazolen
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
CA2014537A1 (en) * 1989-04-26 1990-10-26 Yoshio Hayashi 4-imidazoline derivatives
US4966909A (en) * 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
US5331002A (en) * 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
DE4015535A1 (de) * 1990-05-15 1991-11-21 Basf Ag Verfahren zur herstellung von n-substituierten imidazolen
IT1251488B (it) * 1991-09-17 1995-05-15 Mini Ricerca Scient Tecnolog Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DK28893D0 (da) * 1993-03-15 1993-03-15 Neurosearch As Benzimidazole derivater, deres fremstilling og anvendelse
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
IL124364A (en) * 1995-11-09 2001-08-08 Synthelabo 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol -2(3h)- one derivatives, their preparation and pharmaceutical compositions comprising them
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators

Also Published As

Publication number Publication date
AR008110A1 (es) 1999-12-09
RU2175319C2 (ru) 2001-10-27
CN1116287C (zh) 2003-07-30
AU4067997A (en) 1998-02-20
PL331385A1 (en) 1999-07-05
AU711736B2 (en) 1999-10-21
NZ334403A (en) 2000-09-29
WO1998004135A1 (en) 1998-02-05
ZA976554B (en) 1999-01-25
IL128308A (en) 2004-09-27
US5869509A (en) 1999-02-09
IL128308A0 (en) 1999-11-30
HUP0000063A2 (hu) 2001-01-29
TW467902B (en) 2001-12-11
JP2000516925A (ja) 2000-12-19
HUP0000063A3 (en) 2001-04-28
BR9710793A (pt) 1999-08-17
NO990428D0 (no) 1999-01-29
CN1226803A (zh) 1999-08-25
KR20000029735A (ko) 2000-05-25
US6077861A (en) 2000-06-20
EP0915856A4 (en) 2006-04-12
EP0915856A1 (en) 1999-05-19
CZ32199A3 (cs) 1999-06-16
US6271249B1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
NO990428L (no) Difenylheterocykler som kalsium-kanal-modulatorer
DK1133474T3 (da) 3-Substituerede 4-arylquinolin-2-onderivater som kaliumkanal-modulatorer
PT910425E (pt) Embalagem de cateter
DE69606680D1 (de) 1-Alpha, 26-dihydroxy-D-homo-vitamin D3
NO991384D0 (no) Substituerte heterocykler som anti-tumormidler
DE69927465D1 (de) Kanalzuweisungssystem
DE19681302T1 (de) Verschlußplombe
BR9703909A (pt) Formador de blocos
DE69631604D1 (de) Schnellvernetzende perfluorkautschuk-zusammensetzung
NO974373D0 (no) Transportörspor-tetning
ES1036203Y (es) Aparato de alumbrado empotrado.
FI961508A0 (fi) Ledningskanal som ocksao fungerar som foensterbraede
FI964074A0 (fi) Brandkaempningssystem som anvaender aonga/vaermevaexlare/ackumulatorpanna/golvlistradiator
FI963725A0 (fi) Bastuugn som vaermar vatten
FI960675A0 (fi) Kortslutningsskydd foer en som belastningskoppling fungerande FET-transistor
FI964396A0 (fi) Foerfarande foer framstaellning av inredningsytor som bestaor av traespjaelor
FI964402A0 (fi) Foerfarande foer montering av anordningar som hindlar koerspaorsformning pao vaegytan
FI961646A0 (fi) Foerfarande foer aostadkommande av en masspektrometer som fungerar under tryck
IT241777Y1 (it) Plafoniera ad incasso per controsoffitti
IT241474Y1 (it) Sottopiede per calzatura
KR980003096U (ko) 호안블럭
ES1033732Y (es) Aplique.
BR7702866U (pt) Disposição de calceiro
IT1287101B1 (it) Rivestimento portante-integrativo per gallerie
KR970000156U (ko) 신발중창